Amneal Pharmaceuticals (AMRX) Tops Q3 EPS by 4c, Revenues Beat; Raises FY20 Revenue Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Amneal Reports Third Quarter 2020 Financial Results
November 6, 2020 6:00 AM ESTQ3 2020 Net Revenue of $519 million; GAAP Net Loss of $(9) million; Diluted Loss per Share of $(0.06)
Q3 2020 Adjusted Net Income (1) of $49 million; Adjusted EBITDA (1) of $114 million; Adjusted Diluted EPS (1) of $0.16
Updating 2020 Full Year Financial Outlook
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the Company) announced its results today for the third quarter ended September 30, 2020.
Amneal delivered another strong quarter, providing further evidence that our Amneal 2.0 strategy is positioning the company for sustained growth, said Chirag and Chintu... More
